

Corporate Funded Sponsored Projects Activity

Project Title	Funding Agency
Lipidomic applications in Trauma and Critical Care Research	AB SCIEX
Interleukin-18 blockade in a mouse of heart failure with preserved ejection fraction	AB2 Bio Ltd
Assessment of Harmonization of Serum Albumin Methods: State of the Art	Abbott Laboratories
Master Clinical Trial Agreement	Abbott Vascular, Inc.
Effects of medication candidates on responding maintained by cocaine and its conditional stimuli	AbbVie, Inc.
M12-665 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis Associated Pain	AbbVie, Inc.
Protocol No. M13-393 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I)	AbbVie, Inc.
USpella (Impella 2.5) Data Registry	Abiomed, Inc
Implementation & Evaluation of a Benefit Offset National Demonstration (BOND)	Abt Associates Inc.
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures	Acorda Therapeutics, Inc.
Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficiency of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis.....Protocol #DER-401	Acorda Therapeutics, Inc.
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative PAH QuERI	Actelion
US-Based, Observational, Drug Registry of Opsumit (R) (Macitentan) New Users in Clinical Practice-OPUS, AC-055-503	Actelion
CBH Proposal	
The Use of Star Polymers as Viscosity Modifiers, Dispersants, Antioxidants, and Detergents	Afton Chemical Corporation
Acute Kidney Injury N-gal Evaluation of Symptomatic heart failure Study (AKINESIS)... Protocol# DDDP-09EE-081	Alere
A randomized, parallel-group, double-blind, placebo-controlled, multi-center study of Eculizumab for the prevention of delayed graft function after kidney transplantation in adult subjects at increased risk of delayed graft function	Alexion Pharmaceuticals
An Observational, Non-Interventional , Multi-Center, Multi-National Study of Patients with Atypical Hemolytic-Uremic Syndrome - Registry Protocol No. M11-001	Alexion Pharmaceuticals
A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)	Alnylam Pharmaceuticals Inc.

A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis	Anylam Pharmaceuticals Inc.
Animal Care Services	Amercian International Biotechnology LLC
"START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease." Protocol No. 20110226 Subproject for Institution # PT102264	Amgen, Inc.
A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma	Amgen, Inc.
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Subproject for Institution # PT102264	Amgen, Inc.
Long Term Follow-Up Study of Patients with Hematologic	Amgen, Inc.
Master Clinical Trial Agreement	Amgen, Inc.
Phase II DAS181 Lower Tract PIV Infection in Immunocompromised Subjects	Ansun Biopharma, Inc.
A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less than 18 Years of Age With Hypertension	Arbor Pharmaceuticals LLC
Fishery Entrainment Monitoring Plan	Arcadis
A Phase 3 Randomized, Open-Label Study of Ponatinib Versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	ARIAD Pharmaceuticals, Inc.
Subproject for Institution # PT106191	Ascension Orthopaedics, Inc.
Analysis of multi-target anti-cancer compounds	Astar Biotech LLC
9463-CL-2303 Phase 3 Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis	Astellas Pharma Global Development, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-seropositive Donor	Astellas Pharma Global Development, Inc.
Master Clinical Study Agreement	Astellas Pharma Global Development, Inc.
Protocol #0113-CL-1004 "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)"	Astellas Pharma Global Development, Inc.
A Randomized, Double-Blind, Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin(ASA) in Patients with Acute Ischaemic Stroke or TIA [SOCRATES]	Astra Zeneca

Effects of Myonectin on Cardiac Hypertrophy	Astra Zeneca
Evaluation of ATMi and Irradiation Combinations in Orthotopic Glioblastoma Murine Models	Astra Zeneca
GOG-3004: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy (D0818C0001)	Astra Zeneca
Mouse Model: Epanova and SGL T2 inhibitors in combination for treatment of NASH	Astra Zeneca
A Phase 2, Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke	Asubio Pharmaceuticals, Inc.
ASBI 801 - Simplified-STroke REhabilitation Assessment of Movement (S_STREAM) Scale in Subjects Obtained Between 24 and 48 Hours of a Non-hemorrhagic Ischemic Stroke..... Protocol #ASBI 801	Asubio Pharmaceuticals, Inc.
Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects with Primary Immunodeficiency (PID)- Protocol Number KB052	Atlantic Research Group
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections (ACCUTE)	Atox Bio
AtriCure Synergy Ablation Lesions for Non-Paroxysmal Forms of Atrial Fibrillation Treatment during Concomitant On-Pump Endo/Epicardial Cardiac Surgery	AtriCure, Inc.
Pivotal Study of Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects with Persistent or Long Standing Persistent Atrial Fibrillation with Radiofrequency Ablation	AtriCure, Inc.
A Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries....Protocol #CTP001-5	Avita Medical, LLC
A Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities(RECON) - Protocol No. ANG-CP-007	AxoGen, Inc.
A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury	Banyan Biomarkers, Inc.
Alert-TBix	Banyan Biomarkers, Inc.
A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System	Bard Peripheral Vascular
Tube Launched UAV with Glide to Hover Transition	Barron Associates
Assessment of Tobacco Products Pharmacology and Behaviors	Battelle Memorial Institute
A Phase 3 prospective, uncontrolled, multicenter study evaluating the pharmacokinetics, efficacy safety and immunogenicity of Bax855 in previously treated pediatric patients with hemophilia	Baxter International Inc.
BAY 59-7939/14373 4-week, open-label, multiple-dose study of the safety and the pharmacokinetic and pharmacodynamic properties of the oral direct factor Xa	Bayer Inc.
A Phase II/III Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-Demand and Prophylactic Treatment with BAY 94-9027 in Severe Hemophilia A.....Protocol #BAY 94-9027...Subproject for Institution # PT104546	Bayer Inc.

A Randomized, Double-Blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases (BAY 73-4506/15983)	Bayer Inc.
An Open-Label Phase IIIb Study of Regorafenib in Patients with Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy...Protocol #BAY 73-4506/15967	Bayer Inc.
Master Clinical Trial Agreement	Bayer Inc.
ONC-2013-062 Phase I Trial of Regorafenib and Sildenafil in Advanced Solid Tumors (Study Drug Only)	Bayer Inc.
A Randomized, Double Blind, Placebo Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury	BHR Pharma, LLC
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)	Biogen Idec, Inc.
A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients with Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (dimethyl fumarate) Delayed-Release Capsules (MANAGE)	Biogen Idec, Inc.
Controlled High Risk AVONEX Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance: CHAMPIONS Continuation.....Protocol# US 04-09-AVX	Biogen Idec, Inc.
Master Agreement	Biogen Idec, Inc.
Phase I Trial of Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Glioblastoma Multiforme	Biogen Idec, Inc.
Plegridy™ (peginterferon B-1a) Real World Effectiveness and Safety Observational Program (POP)	Biogen Idec, Inc.
EP Fellowship 2014-2015	Biosense Webster, Inc.
NaviStar ThermoCool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation PMA P0300031/S014	Biosense Webster, Inc.
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation	Biosense Webster, Inc.
ThermoCool Smart Touch Catheter for the Treatment of Symptomatic Paroxysmal	Biosense Webster, Inc.
ThermoCool SmartTouch Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation - IDE Study - Study Start-up Documents	Biosense Webster, Inc.
A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE AD (A Study of the RE-VERsal Effects of Idarucizumab on Active Dabigatran) Trial	Boehringer Ingelheim Pharmaceuticals, Inc.
Proposal to Evaluate the Development of a Heterogeneous Asymmetric Hydrogenation Catalyst	Boehringer Ingelheim Pharmaceuticals, Inc.
The Anti-Inflammatory Effects of Tiotropium Bromide in IL-13 Transformed Human Airway Cells	Boehringer Ingelheim Pharmaceuticals, Inc.
Providing Direct Benefits Counseling in Support of the SSA BASS Efforts to Assist Beneficiaries to Pursue Their Employment Goals	Booz, Allen, Hamilton, Inc.
2014-2015 EP Fellowship	Boston Scientific

CAPT ure Information Via Automatic Threshold Evaluation (CAPTIVATE)	Boston Scientific
Image Ready™ MR Conditional Pacing System (SAMURAI)	Boston Scientific
Longitudinal Surveillance Study of the 4-SITE Lead/Header System (LSS of 4-SITE)	Boston Scientific
Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients (MultiSENSE)	Boston Scientific
AIDS Clinical Trial Group Study Co-Chair	Brigham & Women's Hospital
Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE TIMI58)-Prime Sponsor ASTRA ZENECA	Brigham & Women's Hospital
Evaluation of Yoga for Substance Use Risk Factors in the High School Setting	Brigham & Women's Hospital
Master Service Agreement CALGB/Case Study by BWH	Brigham & Women's Hospital
Master Agreement - Clinical Trial: PSA CALGB Member Institution #375: Cancer and Leukemia Group B Pathology Reimbursement	
Master Clinical Trial Agreement	Bristol-Myers Squibb Company
MB130-045: BMS NASH	Bristol-Myers Squibb Company
BTG-PR005-002- A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFabA versus Placebo with Rescue Treatment for Copperhead Snake Envenomation. BTG International=Sponsor, Chiltern=CRO	BTG International Inc.
A Randomized, Placebo Controlled Multi Center Study of the Efficacy PK and PD of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients	Cadence Pharmaceuticals, Inc.
S-ICD Post Approval Clinical Study (EFFORTLESS)	Cameron Health
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure	Cardioxyl Pharmaceuticals, Inc.
A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndromes	Celgene Corporation
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission	Celgene Corporation
A Phase II Study of the Use of 5-Azacytidine as Pre-Transplant Cyto reduction Prior to Allogeneic Stem Cell Transplatation for High Risk Myelodysplastic Syndromes	Celgene Corporation
Master Clinical Study Agreement	Celgene Corporation

CellDex CDX301-03: CDX for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts	CellDex Therapeutics
Clinical Education for VCU Family Medicine Residents FY15	Chippenham and Johnston Willis Hospital, Inc.
A Multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety, of SA237 as monotherapy in patients wioptica (NMO) and Neu...	Chugai Pharmaceutical Co. LTD
PARACHUTE IV: Percutaneous Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease SPONSOR: CardioKinetix (CRO:Clinipace)	Clinipace Worldwide
Master Research Agreement	Cochlear Americas
Master Agreement	Commonwealth Center for Advanced Logistics Systems (CCALS)
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients with Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy (TREAT-Mayo)	Conatus Pharmaceuticals Inc.
Post-Market Study Plan No. 12-013 "Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair"	Cook Biotech, Inc.
Feasibility Study of Eye Movement Monitoring Using Skin-Like Electronics	CooperVision
A double-Blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema - Study No. CSL830_3001	CSL Behring
Protocol Number CSL830-3002 - "An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema"	CSL Behring
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function	CTI Clinical Trial and Consulting Services
A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia	Cubist Pharmaceuticals, Inc
A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokentics of Ifetroban Injection in Hepatorenal Syndrome (CPT-IFE-001)	Cumberland Pharmaceuticals Inc.
Rheos Pivotal Trial	CVRx, Inc.
ENSURE in AF Study (Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of AF)	Daiichi Sankyo Pharma Development
RA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)....Protocol #ARQ197-A-U302	Daiichi Sankyo Pharma Development
A Prospective, Multi-Center Study of Phasix Mesh for Ventral Incisional Hernia Repair, DVL-HE-011	Davol Inc.
Energy Harvesting: Developing Piezoelectric Materials for Passive Energy Harvesting	Dominion Energy, Inc.
Translational Study 5-Cholesten 3,25-diol 3-Sulfate as New Medicine for Therapy of Metabolic Disorders	DURECT Corporation

Measuring contact pathway biomarkers in subjects diagnosed with hereditary angioedema and non-HAE during and in between and acute attack, or diagnosed with other inflammatory diseases, using novel assays to measure protein markers of inflammatory disease biology, including plasma kallikrein and pKal degradation products	Dyax Corp.
B067: Utility of fibroscan™ in the noninvasive assessment of liver disease	Echosens
CAP Code G7 Fibroscan	Echosens
Open Label Pilot Study W/an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, Efficacy of Perampanel	Eisai, Inc.
CBH - A Randomized Phase 3 Study of LY2835219 verses Erlotinib in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy	Eli Lilly
Translate-ACS Study. Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome....Protocol #H7T-US-B007	Eli Lilly
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Tecemotide Versus Placebo in Subjects with Completed Concurrent Chemo-Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	EMD Serono, Inc
Master Agreement	EMD Serono, Inc
PROTOCOL EC-FV-06: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING EC145 AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL/CAELYX) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER	Endocyte, Inc
EMPOWER Clinical Trial: Vagal blocking for Obesity Control	EnteroMedics
ReCharge	EnteroMedics
Content Evaluation of the Gastroparesis Cardinal Symptom Index-Daily Diary for Use in Patients Diagnosed with Parkinson's Disease and Gastroparesis	Evidera
NASH-EX-1114 Breath ID	Exalenz Biosciences Ltd
The Prediction Value of BreathID, C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis	Exalenz Biosciences Ltd
CBH	
High Flow Humidification Therapy in Cystic Fibrosis	Fisher & Paykel Healthcare, Ltd
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder	Forest Research Institute
A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR)	Genentech, Inc.
A Randomized, Multicenter, Open-Label Trial Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy in Patients with Operable Her2-Positive Primary Breast Cancer	Genentech, Inc.
Genentech Master Agreement	Genentech, Inc.

Richmond Defense & Veterans Brain Injury Center	General Dynamics Information Technology
Choosing Neoadjuvant Chemotherapy versus Hormonal Therapy for Breast Cancer Base (MCC-13311)/ PI Initiated	Genomic Health, Inc.
Defibrotide for Patients with Hepatic Veno-Occlusive Disease: A Treatment IND Study	Gentium
Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation	Genzyme Corporation
SVCARB07609 Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease	Genzyme Corporation
A Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GS-4774 in Combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are Currently not on Treatment	Gilead Sciences, Inc.
(GS-US-321-0106) A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like Molecule 2 (LOXL2) in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).	Gilead Sciences, Inc.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis	Gilead Sciences, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects with Cystic Fibrosis	Gilead Sciences, Inc.
A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy... Protocol# GU-US-300-0140	Gilead Sciences, Inc.
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection	Gilead Sciences, Inc.
comments: HCV Registry Extension protocol for subjects that achieved an SVR	
GS-US-337-0108: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ? Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection	Gilead Sciences, Inc.
GS-US-337-0115 (ION 4) A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection	Gilead Sciences, Inc.
GS-US-337-0123: A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant	Gilead Sciences, Inc.
GS-US-352-0101: A Phase 3, Randomized, Double-blind, Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Gilead Sciences, Inc.
Master Clinical Trial Agreement	Gilead Sciences, Inc.

Protocol GS-US-248-0123, "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection	Gilead Sciences, Inc.
Protocol GS-US-321-0102 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like Molecule 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)	Gilead Sciences, Inc.
Protocol GS-US-321-0105 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety, and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like Molecule 2 (LOXL2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH). - Subproject for Institution # PT103761	Gilead Sciences, Inc.
Heterogeneous Oxidation in Catalysis in Continuous Flow	GlaxoSmithKline
MMR-160 GSK Biologicals' MMR Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine as a First Dose Both Co-Administered with Varivax, Havrix and Prevnar 13 (Subset of Children) to Healthy Children 12 to 15 Months of Age	GlaxoSmithKline
Treatment of Patients with Pulmonary Arterial Hypertension and Right Heart Failure.	GlaxoSmithKline
Development of a novel-antigen diagnostic test for Lyme disease	Global Lyme Diagnostics
Alpha-1 Anti-Tripsin (AAT) in ST-Segment Elevation Acute Myocardial Infarction (STEMI)	Grifols, Inc.
Cardioprotective Effects of Prolastin C in Experimental Acute Myocardial Infarction: A Pre-clinical Translational Study	Grifols, Inc.
Confidential Disclosure Agreement- (GT11307) A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery with Cardiopulmonary Bypass'	Grifols, Inc.
A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome	GW Pharmaceuticals
A randomized, doubleblind, placebo controlled study to investigate the efficacy and safety of cannabidiol (GWP42003P; CBD) as adjunctive treatment for seizures associated with Lennox Gastaut syndrome in children and adults	GW Pharmaceuticals
Master Collaboration Agreement	Health Diagnostic Lab, Inc.
Qualitative Research in Cystic Fibrosis for the Development of a New Patient Reported Outcome (PRO) Measure	Health Research Associates
2014-2015 Heart Failure Fellowship	HeartWare
A Prospective, Single-Arm, Multi-Center Clinical Study in Collaboration with the InterAgency Registry for Mechanically Assisted Circulatory Support (INTERMACS) to Evaluate the Thoracotomy Implant Technique of the HeartWare HVAD System in Patient with Advance Heart Failure	HeartWare
HQP 1001-SCD-007 - A Randomized, Placebo-Controlled, Phase 2 Study of HQK-1001 in Sick Cell Disease	HemaQuest
HEMOSONICS, LLC MASTER AGREEMENT	HemoSonics LLC
HemoSonics-VCU Cardiac Surgery Clinical Study Protocol	HemoSonics LLC

CMV-Neutralizing Activity of PC-Based Vaccines	Hookipa Biotech AG
In Vivo Interferon Gamma Regulation of HLA On Mast Cells In Human Skin	Horizon Pharma
A Multicenter Open-Label Extension Study for Subjects Who Participated in Study B0151003 (ADANTE II) Protocol: B0151005	ICON Clinical Research, Inc.
PRIDE-HD: A Phase 2 Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients with Huntington's Disease	ICON Clinical Research, Inc.
Protocol #A3921095....Study of Oral CP-690, 550 as an induction therapy in subjects with moderate to severe ulcerative colitis	ICON Clinical Research, Inc.
Protocol# B0151003 A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN'S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE)	ICON Clinical Research, Inc.
V419-006 Phase III of V419 in Healthy Infants when given at 2, 4 and 6 months concomitantly with Prevna 13 and Rota Teq	ICON Clinical Research, Inc.
NASH Phase II Protocol IMM124-E-2001 "A phase II, randomized, double-blind, placebo-controlled study of IMM-124E for patients with non-alcoholic steatohepatitis"	Immuron
New Clinical Trial	
Evaluation of the Safety and Efficacy of the OPTIMIZER II System with Active Fixation Leads in Subjects with Heart Failure Resulting from Systolic Dysfunction: FIX-HF-5	Impulse Dynamics, Inc.
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open-Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy with Cataplexy	INC Research, LLC
INCB 18424-268: A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer	Incyte Corporation
A Phase 2 Multicenter, Single Dose, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Evaluating the Safety and Efficacy of Two Doses of Stannosporfin in Combination with Phototherapy in Neonates. Protocol No. 64,185-204	Infacare Pharmaceutical Corporation
The effect of dapson aerosol in the inflamed ferret airway using a novel formulation and delivery device	Inspirex
A Double Blind, Placebo Controlled Trial of Obeticholic Acid in Patients with Moderately Severe Alcoholic Hepatitis (AH) (TREAT - Indiana INT-747))	Intercept Pharmaceuticals Inc.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.....Protocol #PIPE-016	InterMune, Inc.
A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone Protocol No. PIPF-031	InterMune, Inc.
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies	InterMune, Inc.

P261-408- An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects with Seizures Clusters	inVentiv Health Inc.
Training Course for Continuous Regional Anesthesia for Rib Fractures-Tunnel Catheter Placement Technique	Kimberly-Clark Corporation
Kuwait Training Gate-Training and Technical Assistance	Kuwait Training Gate
Subproject for Institution # PT106389	Kuwait Training Gate
Growth of GaN-based heterostructures on Kyma FLAAT substrates	Kyma Technologies, Inc.
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (ATHOS-3)	La Jolla Pharmaceutical Company
Brain-Computer Interface-based Volition Control Device	Ladenburg Funding, Inc. (The)
Cloud Based Collaboration for Clinical Trials, Research and Training	Leidos Biomedical Research
PROPOSAL TO TEST Lu AA21004 AND OTHER COMPOUNDS IN A SUSTAINED ATTENTION TASK (VISUAL SIGNAL DETECTION)IN RATS	Lundbeck, Inc.
A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In Stent Restenosis	Lutonix
YES Graduate Program	Maersk
Evaluation of Purified Poloxamer 188 in Children in Crisis (Epic): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children with Sickel Cell Disease Experiencing Vaso-Occlusive Crisis	Mast Therapeutics, Inc
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickel Cell Disease (EPIC): A Phase 3, Randomized, Double Blind, Placebo-Controlled Multicent Clinical Trail of MST-188 (purified poloxamer 188) Injection in Subjects with Sickel Cell Disease Experiencing Vaso-Occlusive Crisis	Mast Therapeutics, Inc
Subproject for Institution # PT108550	Mathematica
Disability Research Consortium (DRC)	Mathematica Policy Research, Inc.
NIHCR Health Policy Research, Inc.	Mathematica Policy Research, Inc.
Redesigning Diabetes Work Processes for Population-based Primary Care	Mathematica Policy Research, Inc.
Safety Net Hospitals and the ACA	Mathematica Policy Research, Inc.
A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers	McGuff Pharmaceuticals, Inc
An Observational Study to Evaluate the Relationship of Nasal Mucus Properties and Symptoms in Acute Rhinosinusitis	McNeil Consumer Healthcare
Biostatistics	McNeil Consumer Healthcare
Effect of Long Acting Antihistime on Opioid-Induced Pruritus: A Double-Blind Placebo Controlled Study	McNeil Consumer Healthcare
Subproject for Institution # PT109242	McNeil Consumer Healthcare

Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects with Liver Fibrosis (CENTAUR)	Medpace, Inc.
AdaptResponse	Medtronic
Artifact-free Cone-beam CT Construction for Pedicle Screw and DBS Probe Localization	Medtronic
PainFree SST Clinical Study	Medtronic
Renal Denervation in Patients with Uncontrolled Hypertension (Symplicity HTN-3)....Protocol #IP125	Medtronic
A phase I Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human CMV Vaccine(V160) in Healthy Adults	Merck & Co., Inc.
A Phase III, Double Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)....Protocol #V212-001	Merck & Co., Inc.
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001 AM2) (MODIFY I)	Merck & Co., Inc.
Cellular Responses to CMV	Merck & Co., Inc.
Immune Responses to CMV in Pregnancy	Merck & Co., Inc.
Letermovir Mechanism of Action	Merck, Sharp, & Dohme Corporation
Merck LKR145529 NASH biomarkers human study	Merck, Sharp, & Dohme Corporation
Three Assay Validations on Cascadion SM Analyzer	Microgenics Corporation
A Phase 3, Randomized, Double-Blind Multicenter Study Comparing Oral MLN9708 C16014 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	Millennium Pharmaceuticals
A Randomized, Open-Label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma	Millennium Pharmaceuticals
MCC 03740: Phase 1 Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Millennium Pharmaceuticals
Phase I Trial of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....Protocol #RM-CLL-PI-0006	Millennium Pharmaceuticals
DAR Services for Molecules for Health	Molecules for Health
Continuous Production of Cobalt Nanoparticles	Nanofoundry, LLC.
Evaluation of Oral Antibiotic Use with Nasal Saline Irrigation for the Treatment of Rhinosinusitis	NeilMed Pharmaceuticals, Inc.
A Prospective Controlled Post-Approval Study of NeoMend ProGEL Sealant in the Treatment of Visible Pleural Air Leaks after Standard Pleural Closure	Neomend, Inc.
Confidential Disclosure Agreement - "A Prospective, Randomized Study to Compare Progel® Sealant to Gelfoam® Plus as an Adjunct for the Control of Bleeding after Conventional Hemostasis in Subjects Undergoing Thoracic Aortic Surgery," NEO13-100	Neomend, Inc.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Injury (TBI)

Neuren Pharmaceuticals Limited

Anti-epileptogenic Effects of Novel Proximagen Compounds in the SE Model

NeuroDetective International, Inc.

A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer

NewLink Genetics Corporation

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute Pancreatic Cancer Vaccine in Subjects with Surgical Resected Pancreatic Cancer....Protocol #NLG0405

NewLink Genetics Corporation

NNS RFQ# 6000435719, Independent Study on the Licensing Feasibility of Advanced Nuclear Reactor Concepts Using Natural Circulation

Newport News Shipbuilding

Robotics for Tank Inspection Phase 2

Newport News Shipbuilding

A 24 month, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants. (RAD001H)

Novartis Pharmaceuticals Corporation

A 24-Week, open-label, parallel-group, interventional phase IV study comparing Tobramycin Inhalation Powder administration once daily continuously versus TIP administration bid in 28 day on/off cycles for the treatment of pulmonary Pseudomonas Aeruginosa in patients with Cystic Fibrosis

Novartis Pharmaceuticals Corporation

A 26 Week, Randomized, Active-Controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus and inhaled Corticosteroid in Adolescent and Adult Patients with Persistent Asthma

Novartis Pharmaceuticals Corporation

A 5-year, Prospective, Non-Intentional Multicenter Registry in Sickle Cell Disease patients...Protocol# C1CL670AUS38...Subproject for Institution # PT102299

Novartis Pharmaceuticals Corporation

A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 after Switching to Nilotinib

Novartis Pharmaceuticals Corporation

A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-rearranged (ALK-positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Novartis Pharmaceuticals Corporation

A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP....Protocol # CACZ885M2301.....Subproject for Institution # PT102299

Novartis Pharmaceuticals Corporation

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)

Novartis Pharmaceuticals Corporation

Compassionate Use of Open-Label Midostaurin in a Patient, with Aggressive Systemic Mastocytosis

Novartis Pharmaceuticals Corporation

CPKC412AUS23: Midostaurin to Prevent Relapse after Transplantation in FLT3-ITD Mutated AML

Novartis Pharmaceuticals Corporation

CTBM100C2412: A multi-center, human factors engineering (HFE) usability study in cystic fibrosis patients to validate the approved instructions for use (IFU) of TOBI Podhaler (tobramycin inhalation powder) using placebo capsules	Novartis Pharmaceuticals Corporation
Interleukin-1 blockade with Canakinumab to Improve Exercise Capacity in Patients with Chronic Systolic Heart Failure and Elevated hs-CRP. A Randomized, Double-blind, Placebo-controlled, Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events..... Protocol #CACZ885M2301 CANTOS SubStudy	Novartis Pharmaceuticals Corporation
LCZ696 for Cardio-Renal Protection in a Translational Rabbit Model of HFrEF	Novartis Pharmaceuticals Corporation
Master Agreement	Novartis Pharmaceuticals Corporation
Prospective, double-blind, multicenter study evaluating the safety of repeat doses of IV serelaxin in subjects with chronic heart failure.	Novartis Pharmaceuticals Corporation
CBH	
Serelaxin Therapy for Ischemic Cardiomyopathy	Novartis Pharmaceuticals Corporation
Subproject for Institution # PT102299	Novartis Pharmaceuticals Corporation
A single arm, phase II, open-label study to determine the efficacy of 100 mg twice daily oral dosing of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease	
A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of ProQuad Vaccine When Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers - Protocol V59P21	Novartis Vaccines and Diagnostics
A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants. Protocol No. V59P23	Novartis Vaccines and Diagnostics
Master Clinical Trial Agreement	Novartis Vaccines and Diagnostics
A Self Assembling Gel with Antimicrobial and Antioxidant Properties for Burns	Novion Technologies
Topical Silver Sulfadiazine with Efficacy and Toxicity Profile	Novion Technologies
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial On Safety of Monthly Therapy with rFXIII in Subjects with Congenital FXIII Deficiency...Protocol# F13CD-3720	Novo Nordisk Pharmaceuticals, Inc.
Characterizing the In Vitro Effects of Pro-Hemostatic Antibodies in Blood from Severe Hemophiliacs	Novo Nordisk Pharmaceuticals, Inc.
Impact of Coated Platelet Levels on rFVIIa Response as Measured by Thrombin Generation and Platelet Function	Novo Nordisk Pharmaceuticals, Inc.
Master Clinical Trial Agreement	Novo Nordisk Pharmaceuticals, Inc.
Surveillance of Safety and Efficacy of Wilate in Patients with Von Willebrand Disease (Wil 20)	Octapharma Incorporated
"Clinical Trial of the On-X Valve using low Dose Anticoagulation"	On-X Life Technologies

Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin) in Combination with Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors... Protocol# REO 16	Oncolytics Biotech, Inc.
Randomized, Double-Blind, Multicenter Two-Stage Adaptive Phase II Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or after Prior Platinum-Based Chemotherapy... Protocol# REO 18	Oncolytics Biotech, Inc.
Preclinical Studies Examining Interactions Between the HDAC Inhibitor Vorinostat and the Proteasome Inhibitor Carfilzomib in Malignant Human Hematopoietic Cells in Vivo and in Vivo	Onyx Pharmaceuticals, Inc.
Multi-Center Phase 3 Trial of Minocycline HC1 1mg Microspheres for the Use in Subjects with Peri-Implantitis: Clinical and Microbiological Evaluations	OraPharma Inc
Cannabinoid Receptor Agonists for Treatment of Chronic Pain	Organix, Inc.
CT Confirmation of Component Rotation in a Cadaver Model BALanced TKA Using Verasense	OrthoSensor Inc.
BMT-302	Palatin Technologies
A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis	Pfizer Inc., U.S. Pharmaceuticals Group
A Phase 3, Randomized, Double-Blind Study of PF-05280586 Versus Rituximab for the First-Line Treatment of Patients with CD20-Positive, Low Tumor Burden, Follicular Lymphoma	Pfizer Inc., U.S. Pharmaceuticals Group
A Selective Metabolic Approach to Increase Phenylephrine Oral Bioavailability, Part 1: Establish the Approach	Pfizer Inc., U.S. Pharmaceuticals Group
An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic and 48-Week Safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the Treatment of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2-18 Years of Age	Pfizer Inc., U.S. Pharmaceuticals Group
CBH Agreement: "A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of F--04447943, Co-Administered with and Without Hydroxyurea, in Subjects with Stable Sickle Cell Disease."	Pfizer Inc., U.S. Pharmaceuticals Group
Identifying a Hemostatic Assay that is Predictive of Clinical Efficacy in Blood from Hemophiliacs	Pfizer Inc., U.S. Pharmaceuticals Group
Master Clinical Trial Agreement	Pfizer Inc., U.S. Pharmaceuticals Group
Protocol #A3921139....A Multi-Center, Open-Label Study of CP-690, 550 In Subjects With Moderate to Severe Ulcerative Colitis (OCTAVE)	Pfizer Inc., U.S. Pharmaceuticals Group
Protocol #A7281009-9002:A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT)...Subproject for Institution # PT106040	Pfizer Inc., U.S. Pharmaceuticals Group
Protocol A7281010: A Multicenter Open-Label Extension Study to Assess Long-Term Safety of PF-00547659 in Subjects with Ulcerative Colitis (TURANDOT II)... Subproject for Institution # PT106040	Pfizer Inc., U.S. Pharmaceuticals Group
Subproject for Institution # PT111280	Pfizer Inc., U.S. Pharmaceuticals Group
Virginia Women's Stroke Prevention Initiative	Pfizer Inc., U.S. Pharmaceuticals Group

Epidemiology and Community Health	Pfizer Pharmaceuticals
Medical and Academic Partnership Visiting Professor in Rheumatology	Pfizer Pharmaceuticals
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of R04995819 Versus Placebo, as Adjunctive Therapy in Patients with Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment - Protocol No. BP25712	Pharmaceutical Research Associates
A Two Part, Phase 1, Multicenter, Open-Label, Study of DKN-01 Given Intravenously Part A: A Dose Escalation Study in Patients with Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)	Pharmaceutical Research Associates
A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765) in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed and Refractory Multiple Myeloma	Pharmacyclics, Inc
Pharmacyclics Master Agreement	Pharmacyclics, Inc
COPD Wet & Dry Weight	Philips Healthcare
Philips Master Agreement	Philips Healthcare
Image-guided Radiation Therapy and Brachytherapy: a Virtual Clinical Trial Database for Locally Advanced Cervical Cancer & Intermediate Risk Prostate Cancer	Philips Radiation Oncology Systems
Antimicrobial Surface Modifiers for Urinary Catheters	Polymer Exploration Group LLC
Catheter Surfaces with Antimicrobial and Low Protein and Cell Adhesion Properties	Polymer Exploration Group LLC
A 14 Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures	PPD Development, LLC
A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair (PPD)	PPD Development, LLC
An Open Label, Multicenter, Follow-Up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150mg/day in Subjects Aged 16 Years or Older Suffering from Epilepsy	PPD Development, LLC
Fishery Monitoring of Curles Neck Creek	Pruitt Companies
A Four-Year Blinded-Outcomes Follow-Up Study of Patients Who Received Stannosporfin or Placebo in Clinical Trial - Protocol No. 64,185-205	Quintiles, Inc.
A Phase 3, Double-Blind, Randomized, Efficacy and Safety and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease	Quintiles, Inc.
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.	Quintiles, Inc.
A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis", ROF-NASH-205	Quintiles, Inc.

A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy

Quintiles, Inc.

PT110686: Confidential Disclosure Agreement: Protocol INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced Or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy

PT110686 has merged with PT111705

Multicenter, Open-label, Safety and Pharmacokinetic Study of Oral Codeine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Post-Procedural Pain

Quintiles, Inc.

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE AHF]
SPONSOR: CARDIORENTIS

Quintiles, Inc.

AQT90 FLEX BNP Reference Interval DC-047163

Radiometer Medical

AQT90 FLEX BNP, NT-proBNP Method Comparison Style

Radiometer Medical

IMPACT MODELING OF EO MATERIALS

Raytheon Company

International Scholars in Addiction Studies Scholarship Program

Reckitt Benckiser Pharmaceuticals Inc

A Point-Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients with Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors

REGISTRAT-MAPI

Respicardia Inc. Pivotal Trial of the remede System Clinical Investigational P1

Respicardia

ARTUS wet and dry weight

Respironics, Inc.

RFHE 4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, & Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment & Overt Hepatic Encephalopathy

Salix Pharmaceuticals, Inc.

RFHE4043PK- RIFAXIMIN 550 MG with Severe Hepatic impairment and overt hepatic encephalopathy

Salix Pharmaceuticals, Inc.

RFHE4044: A MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIFAXIMIN 550 MG WITH AND WITHOUT LACTULOSE IN SUBJECTS WITH A HISTORY OF RECURRENT OVERT HEPATIC ENCEPHALOPATHY ("Study")

Salix Pharmaceuticals, Inc.

RNLC2131: A Randomized, Double-Blind, Placebo-Controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets For the Prevention of Complications in Subjects with early DECompensated Liver Cirrhosis

Salix Pharmaceuticals, Inc.

A prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Sanofi US

A Randomize, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy & Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)	Sanofi US
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY)	Sanofi US
An International, Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two-Year Treatment with Teriflunomide 7 mg Once Daily and 14 mg, Once Daily, Versus Placebo in Patients with a clinical Episode Suggestive of Multiple Sclerosis Plus a Long-Term Extension Period..... Protocol #EFC6260....Subproject for Institution # PT102597	Sanofi US
Master Agreement Sanofi US Services Inc.	Sanofi US
Evaluation of the Beckman Coulter DxN HCV Viral Load Assay as an Aid in the Management of HCV-Infected Individuals Undergoing Antiviral Therapy....Protocol #HCV-01-11....Subproject for Institution # PT106001	SC Liver Research Consortium, LLC.
Master Agreement	SC Liver Research Consortium, LLC.
IMPROVE-IT.....Protocol #P0413	Schering
A Phase 2 Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above	Seattle Genetics
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (Brentuximab Bedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)	Seattle Genetics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and VHP (A+CHP) versus CHOP in the Frontline Treatment of Patients with CD30-positive Mature T-cell Lymphomas: the ARROVEN Study	Seattle Genetics
Master Agreement IS	Seattle Genetics
JL Note: 5 year term	
Master Agreement Effective date: November 15, 2012	
Master agreement is effective thru November 14, 2017.	
Phase 2 Study of Brentuximab Vedotin with RCHOP for Diffuse Large B-Cell Lymphoma (Protocol SGN35-017)	Seattle Genetics
SGN35-016 A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)	Seattle Genetics

SenoRx Contura Overnight Treatment Trial: Safety and Feasibility of Short-Course, Accelerated, Hypofractional Partial Breast Radiotherapy in Women wit early Stage Breast Cancer Using the Contura: A Phase II Trial Protocol# S09-001	SenoRx
Cardioprotective effects of SP16 in experimental acute myocardial infarction: a Preclinical Translational Study	Serpin Pharma
Specimen Collection in the Emergency Department for The Assessment of Clinical Performance of Troponin Assays	Siemens Healthcare Diagnostics, Inc.
Confidential Disclosure Agreement: troponin immunoassay tests development project	
Siemens Master Research Agreement	Siemens Medical Systems, Inc.
Master Agreement: Siemens Software Grant for VCU Engineering Education	Siemens PLM Software
Siemens Software Grant for VCU Engineering Education	Siemens PLM Software
Master Agreement CRB SSS-S-13-003178: Influenza Studies IRC003 and IRC004 Domestic Operation	Social & Scientific Systems, Inc.
Protocol IRC 003 entitled, "A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) versus Oseltamivir for the Treatment of Influenza	Social & Scientific Systems, Inc.
Evaluating the use of polymyxin B Hemoperfusion in a Randomized controlled trial of adults treated for endotoxemia and septic shock...Protocol: SDI-PMX-NA001	Spectral Diagnostics Inc.
A Multicenter, Open Label Trail of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma....Protocol# PXD101-CLN-19	Spectrum Pharmaceuticals
MCC-12517: Phase I Study of Belinostat and Bortezomib in Replapsed of Refractory Acute Leukemia/Myelodysplastic Syndrome Protocol: MCC-12517	Spectrum Pharmaceuticals
A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Single-Lobe Treatment of Severe Emphysema	Spiration, Inc.
The Surpass IntraCranial Aneurysm Embolization System Pivotal TRial to treat large OR giant wide neck aneurysms (SCENT)	Stryker Biotech
Master Agreement	Sunovion
Protocol for Evaluating the Effects of SEP-363856 on Prime-Induced Reinstatement of Extinguished Lever Pressing Previously Reinforced with Cocaine Infusion in Rats	Sunovion
Protocol for Evaluating the Effects of SEP-363856 on Cue-Induced Reinstatement of Extinguished Lever Pressing Previously Reinforced with Cocaine Infusion in Rats	
C-Pulse System US IDE Study	Sunshine Heart Inc.
RA-142: SynCardia Freedom Driver System Study	SynCardia Systems, Inc.
Syncardia 50cc TAH-t as a Bridge to Transplant	SynCardia Systems, Inc.

SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)	SynCardia Systems, Inc.
The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study	SynCardia Systems, Inc.
Study of Azacitidine with or without Birinapant in subjects with MDS or CMMoL	TetraLogic Pharmaceuticals
A multinational, multicenter, randomized, parallel-group STUDY PERFORMED IN SUBJECTS WITH Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week, compared to placebo in a double-blind design....(Subproject for Institution # PT103086)...Protocol# MS-GA-301	Teva Neurosciences, Inc.
A Multicentered Evaluation of Octreotide for Secondary Bleeding Prophylaxis in Patients with LVADs	Thoratec Corporation
Driveline Silicone Skin Interface (SSI) Registry Protocol	Thoratec Corporation
HeartMate III	Thoratec Corporation
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients...Protocol #ROADMAP	Thoratec Corporation
Safety and Efficacy of Octreotide in Left Ventricular Assist Device (LVAD) Associated Gastrointestinal (GI) Bleeding-CSMS995AUS63T (NOVARTIS providing drug)	Thoratec Corporation
Subproject for Institution # PT111425	Thoratec Corporation
TH-CR-406/SARC021 - A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Threshold Pharmaceuticals
A Non-Interventional, Long-Term, Post Marketing registry of Patients Treated with CIMZIA for Crohns Disease....Protocol #C87075	UCB BioSciences, Inc.
Protocol #SP0980 - Open Label Single-Arm, Explorative Study to Evaluate Tolerability and Efficacy of Locosamide When Added to Levetiracetam (VERVE)	UCB BioSciences, Inc.
The effect of rotigotine on motor symptoms in patients with advanced Parkinson's Disease with motor fluctuations and gastroparesis Phase 3B Study (SP1055 Study)	UCB BioSciences, Inc.
Master Agreement	UCB Pharma, Inc.
The Sentinel 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalization among infants born at 29 to 35 weeks	United BioSource Corporation
A Phase III, International, Multi-Center, Randomized Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy	United Therapeutics, Inc.
An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension-A Long-Term Follow-Up to Protocol TDE-PH-310.	United Therapeutics, Inc.
Master Varian Agreement	Varian Medical Systems
VMA - P6: Dose Reconstruction for MR-guided Intracavitary Brachy.....Subproject for Institution # PT105301	Varian Medical Systems

A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation - Protocol No. VX09-809-102	Vertex Pharmaceuticals, Inc
Master Agreement	Vertex Pharmaceuticals, Inc
VF Circle of Life and CF Focus	Vertex Pharmaceuticals, Inc
VX11-770-109 - A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation	Vertex Pharmaceuticals, Inc
VX12-770-112 - A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation	Vertex Pharmaceuticals, Inc
VX12-809-105 - A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	Vertex Pharmaceuticals, Inc
Medicaid Patient-Centered Medical Home: Costs, Outcomes, and Challenges	Virginia Premier Health Plan, Inc.
Outcomes AlloMap Registry (OAR) Study	XDx Incorporated
Assessment of the bactericidal activity of vaccination induced antibody in canines	Zoetis
Hospital Wearable Defibrillator Inpatient Study	Zoll